EUCTR2018-004868-57-FR进行中（未招募）1 期
Phase 2, Open label Study of DS-8201a, an Anti-HER2-AntIbody Drug Conjugate (ADC) for advanced BreaSt Cancer patients, with biomarkers analysis to characterize response/resistance to therapY - DAISY
ICANCER0 个研究点目标入组 162 人开始时间: 2019年6月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 162
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patient must have signed a written informed consent form prior to any study specific procedures. When the patient is physically unable to give his/her written consent, a trusted person of his/her choice, independent from the investigator or the sponsor, can confirm in writing the patient’s consent.
- •2. Female or male subjects aged =18 years.
- •3. Patient with histologically-confirmed diagnosis of invasive breast cancer. Tumors can be either HER2 IHC3+/ISH positive or IHC2+/ISH positive or IHC2+/ISH negative or IHC1+ or IHC0+, of most recent tumor tissue sample available.
- •4. Patient with a documented radiologic metastatic progression.
- •5. Patient considered by the investigator as not amenable to any other validated therapeutic option, after at least 1 line of chemotherapy in metastatic setting. Patient must have been previously treated with anthracyclines and taxanes (in (neo-)adjuvant and/or metastatic setting). Additionally:
- •Patient with HER2 over-expressing (IHC3+ and IHC2+/ISH+) tumor must have been treated and have progressed on trastuzumab and on TDM-1. Prior treatment with pertuzumab is not required.
- •Patient with HER2 negative (IHC0, 1+, and 2+/ISH-) and hormone receptor positive (ER+ and/or PR+) tumor must be resistant to endocrine therapy and CDK4/6 inhibitors, and must have been treated with capecitabine.
- •6. Non-bone metastatic site easily accessible to biopsy.
- •7. Presence of at least one measurable lesion according to RECIST v1.1.
- •8. Patient with WHO performance status =1.
- •9. Adequate bone marrow function: absolute neutrophil count (ANC) =1.5 × 109/L, platelet count =100 × 109/L, and hemoglobin =9 g/dL (transfusion is not allowed within 1 week prior to baseline assessment).
- •10. Adequate liver function: total bilirubin level =1.5 × the upper limit of normal (ULN) range if no liver metastases or <3 x ULN in the presence of documented Gilbert’s Syndrome or liver metastases. AST and ALT levels =3 × ULN (AST and ALT= 5 ULN when documented liver metastasis).
- •11. Adequate blood clotting function: International Normalized Ratio (INR)/Prothrombin Time (PT) and activated Partial Thromboplastin Time (aPTT) =1.5 x ULN.
- •12. Adequate renal function: estimated creatinine clearance =30 mL/min according to the Cockcroft-Gault formula or serum creatinine =1.5 x ULN.
- •13. Adequate cardiac function: left ventricular ejection fraction (LVEF) = 50% at baseline as determined by either echocardiogram (ECHO) or multigated acquisition (MUGA) scan within 28 days before inclusion.
- •14. Male and female subjects of reproductive/childbearing potential must agree to use of a highly effective contraception for subjects throughout the study and for at least 4.5 months after last study treatment administration if the risk of conception exists.
- •15. Women of childbearing potential must have a negative serum pregnancy test within 14 days of enrolment or urine pregnancy test 72 hours prior to enrolment.
- •16. Patient is willing to comply with 2 sequential tumor biopsies (baseline and at first progression), and with a series of blood samples throughout the study.
- •17. Patients must be affiliated to a Social Security System.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 62
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 100
排除标准
- •1. Patient with a breast cancer amenable for resection or radiation therapy with curative intent.
- •2. Patient has spinal cord compression or clinically active central nervous system metastases, defined as untreated and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Subjects with clinically inactive brain metastases may be included in the study. Subjects with treated brain metastases that are no longer symptomatic and who require no treatment with corticosteroids or anticonvulsants may be included in the study if they have recovered from the acute toxic effect of radiotherapy.
- •3. Patient with bone metastatic disease only.
- •4. Patient with multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease, other solid tumors curatively treated, or contralateral breast cancer.
- •5. Persistent unresolved toxicities with grade =2 (except alopecia and renal function). Subject with chronic Grade 2 toxicities may be eligible per the discretion of the Investigator after consultation with the Sponsor (eg, Grade 2 chemotherapy-induced neuropathy).
- •6. Patient receiving treatments such as chemotherapy ) within 3 weeks before inclusion , immunotherapy within 4 weeks before inclusion, radiotherapy within 4 weeks or major surgery within 4 weeks. Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry and/or during study participation.
- •7. Patient using drugs that could have pharmacokinetics interaction with investigational drugs. Concomitant use of strong CYP3A4 inhibitors or OATP 1B inhibitors should be avoided...reaction.
- •8. Patients with a concomitant use of chronic systemic (IV or oral) corticosteroids or other immunosuppressive medications except for managing adverse events (inhaled steroids or intra articular steroid injections are permitted in this study.) Subjects with bronchopulmonary disorders who require intermittent use of bronchodilators (such as albuterol) will not be excluded from this study.
- •9. Patient with history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- •10. Patient with clinically significant corneal disease in the opinion of the Investigator.
- •11. Known prior severe hypersensitivity to investigational product or any component in its formulation, including known severe hypersensitivity reactions to study drug (NCI CTCAE v5.0 Grade =3).
- •12. Patient has a history of severe hypersensitivity reactions to other monoclonal antibodies.
- •13. Patients previously treated with topoisomerase 1 inhibitor.
- •14. Patient has substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation of the subject or evaluation of the clinical study in the opinion of the Investigator.
- •15. Known history of testing positive for HIV or known acquired immunodeficiency syndrome.
- •16. Known active hepatitis B virus or hepatitis C virus infection at screening.
- •17. Active infection requiring systemic therapy (as IV antibiotics, antivirals, antifungals,…).
- •18. Other severe acute or chronic medical conditions or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associa
研究者
相似试验
已完成
2 期
HERALD StudyJPRN-jRCT2080224635Aichi Cancer Center Hospital60
已完成
2 期
Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers AnalysisBreast TumorsNCT04132960UNICANCER186
已完成
Unknown
HERALD TR studysolid malignanciesJPRN-jRCT1080224684ational Cancer Center Hospital East65
进行中（未招募）
1 期
Testing the Biological Effects of DS-8201a on Patients With Advanced CancerAdvanced Malignant Solid NeoplasmHER2-Positive Breast CarcinomaMetastatic Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmUnresectable Malignant Solid NeoplasmNCT04294628National Cancer Institute (NCI)62
招募中
2 期
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell TumorOsteosarcomaRecurrent OsteosarcomaDesmoplastic Small Round Cell TumorRecurrent Desmoplastic Small Round Cell TumorRecurrent Kidney Wilms TumorRefractory Desmoplastic Small Round Cell TumorRefractory Wilms TumorWilms TumorNCT04616560National Cancer Institute (NCI)55